60 Degrees Pharmaceuticals Inc (SXTPW)

60 Degrees Pharmaceuticals reports three cures in babesiosis expanded access trialMarch 11, 2026 11:13 AM
IH Market News
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) announced that all three patients enrolled in its expanded access study for relapsing babesiosis were successfully cured after completing a treatment regimen based on tafenoquine, according to a company press release.Despite the positive clinical update, the company’s stock has struggled over the past year. Shares recently traded at about $1.88, representing a decline of roughly 72% over the past 12 months and remaining close to a 52-week low of $1.36. The stock’s beta of 2.71 reflects the elevated volatility typically associated with early-stage biotechnology firms. Analysts currently maintain a strong buy consensus, with price targets ranging from $11.20 to $24, suggesting notable potential upside if the therapy advances through regulatory pathways.The open-label, multi-center study is evaluating the safety and effectiveness of the ARAKODA-based tafenoquine regimen in combination with atovaquone and other antimalarial or antibiotic therapies. The trial focuses on immunocompromised patients suffering from relapsing babesiosis who previously failed standard treatments. The research is intended to validate findings from a 2024 publication by the Yale School of Public Health in the journal Clinical Infectious Diseases.Patients in the trial receive tafenoquine for up to one year, continuing treatment until two consecutive negative PCR tests for Babesia parasites are obtained and symptoms resolve. A patient is considered cured if no evidence of infection appears 60 to 90 days after treatment ends, confirmed through an FDA-approved RNA amplification test that is at least 1,000 times more sensitive than standard commercial RT-PCR diagnostics.The first two patients achieved cures using a triple combination of tafenoquine, atovaquone and an antibiotic. The third patient was treated successfully with a four-drug regimen consisting of atovaquone, azithromycin, proguanil and weekly tafenoquine.Including previously published Yale data, a total of seven patients have now been evaluated. According to the company, the combined evidence indicates that the cure rate for relapsing babesiosis in immunocompromised individuals may approach 100% when weekly tafenoquine is added to an atovaquone-based treatment and continued until two negative PCR tests are recorded.Despite the encouraging clinical findings, the company’s financial performance remains modest. Revenue over the twelve months through the second quarter of 2025 totaled approximately $980,000, although revenue growth accelerated by 129%. The company remains unprofitable, reporting negative EBITDA of $7.63 million.Babesiosis is a tick-borne infection frequently seen as a co-infection in patients with Lyme disease. Symptoms can include fever, chills, sweating and fatigue, and the illness can become life-threatening in elderly or immunocompromised individuals. Currently, there are no FDA-approved treatments or vaccines specifically for babesiosis.Tafenoquine itself is not approved by the U.S. Food and Drug Administration for the treatment of babesiosis. However, the drug is approved in the United States as a malaria prevention therapy under the brand name ARAKODA.Separately, 60 Degrees Pharmaceuticals has recently faced several corporate developments. The company received a delisting notice from Nasdaq after failing to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days, prompting exchange staff to determine that its common shares and warrants should be removed from the Nasdaq Capital Market.In another update, the company announced a partnership with GoodRx aimed at offering discounts on prescriptions for ARAKODA, potentially providing eligible consumers with savings of up to 30%.The company has also exercised an option to negotiate an exclusive licensing agreement with Florida State University related to large-scale purification techniques for castanospermine. The compound, derived from seeds of the Australian chestnut tree, has demonstrated potential in animal studies for influencing carbohydrate metabolism and modifying disease outcomes.60 Degree Pharmaceuticals stock price

Original: 60 Degrees Pharmaceuticals reports three cures in babesiosis expanded access trial

Looks like a pump for an offering coming

SXTP.....................https://stockcharts.com/sc3/ui/?s=SXT&Pp=w&b=5&g=0&id=p86431144783

This is ready huge volume

established a fresh position just under $3. Taking everything off the table turned out to be a good move, probably makes sense in general with these biotechs to make that almost a rule, Downside from here, sure there is, but this is as good as any a place to put a mark in the sand. Any movement past 4 bucks I would take some profit.

In our exclusive interview, Geoff Dow, President and CEO of 60 Degrees Pharmaceuticals (Nasdaq: SXTP), breaks down the company’s commercial growth plan for ARAKODA® (tafenoquine) and the potential expansion into babesiosis, a tick-borne disease with no FDA-approved treatments today.

60 Degrees Pharma (Nasdaq: SXTP) CEO Geoff Dow on Scaling ARAKODA Revenue + Babesiosis Upside



Daily Chart....big move up in OBV
https://schrts.co/ZTWauqZt

60 Degrees Pharmaceuticals shares slide after unveiling GoodRx collaborationFebruary 2, 2026 11:07 AM
IH Market News
Shares of 60 Degrees Pharmaceuticals Inc (NASDAQ:SXTP) fell about 16.9% in premarket trading on Monday after the company announced a new partnership with GoodRx (NASDAQ:GDRX) aimed at expanding access to its malaria prevention treatment, ARAKODA.The deal will allow eligible consumers to receive discounts of up to 30% on ARAKODA (tafenoquine), which is currently the only FDA-approved, once-weekly prescription medication for malaria prevention available in the United States. Through GoodRx’s network, patients will be able to obtain the drug at more than 70,000 pharmacies nationwide starting February 2, 2026, or opt for home delivery where available.ARAKODA is primarily prescribed to travelers visiting malaria-endemic regions. The therapy was developed by the Walter Reed Army Institute of Research and received FDA approval in 2018. Its long terminal half-life of roughly 16 days enables less frequent dosing compared with other prophylactic malaria treatments.The standard dosing schedule involves an initial loading phase of two 100 mg tablets taken daily for three days prior to travel, followed by a maintenance dose of two 100 mg tablets once weekly during travel for up to six months, and a final two-tablet dose in the week after returning.Despite the potential for broader patient access through the GoodRx platform, the market reacted negatively to the announcement, with investors pushing the stock sharply lower in early trading.60 Degree Pharmaceuticals stock priceGoodRx stock price

Original: 60 Degrees Pharmaceuticals shares slide after unveiling GoodRx collaboration

wow not that I called it, but it did fall back to the 3s for a morning, I bought a couple hundred shares and sold for a quick profit but not enough to make it worth it. Thats fine, I believe it will make another trip back into the 3s where I think its a buy.

60 Degrees Pharmaceuticals shares slide after Nasdaq flags delisting riskJanuary 26, 2026 3:44 PM
IH Market News
Shares of 60 Degrees Pharmaceuticals Inc (NASDAQ:SXTP) sank 22.4% on Monday after the company said it had received a notice from Nasdaq indicating that its securities no longer meet listing requirements.The drug developer disclosed that it was notified on January 20, 2026 by Nasdaq’s Listing Qualifications Department that staff had determined to delist the company’s common shares and warrants from The Nasdaq Capital Market.Nasdaq said the decision was based on the company’s failure to maintain a minimum bid price of $1.00 for at least 30 consecutive business days, putting it in breach of Nasdaq Listing Rule 5550(a)(2). While issuers are often given up to 180 days to regain compliance, Nasdaq staff concluded that 60 Degrees Pharmaceuticals does not qualify for a grace period because it carried out a 1-for-5 reverse stock split on February 24, 2025, within the past year.The company’s warrants are also facing removal under Nasdaq Listing Rule 5560(a), which requires the underlying common stock to remain listed on the exchange.60 Degrees Pharmaceuticals said it has paid the $20,000 hearing fee and formally requested an appeal before a Nasdaq panel. This request temporarily halts the suspension of trading and the filing of Form 25-NSE while the appeal is under review. However, the company cautioned that there is no guarantee the panel will approve continued listing.60 Degree Pharmaceuticals stock price

Original: 60 Degrees Pharmaceuticals shares slide after Nasdaq flags delisting risk

as I said, our time will come, and it did today. Record volume and a high in the 8s thats 4x yesterdays close. I sold all my shares averaging probably in the upper 5s, granted I couldve done a lot better but theres no way anyone could have predicted the pump that ensued, it was truly breathtaking. The news clearly didnt match the price or volume action. As always, the price will retreat, how far it could go back into the 2s Im not kidding. I would consider buying in the 3s, maybe, but give it some time to get there, theres nothing that can help sustain price.

SXTP................................................................p/m

Pump it $3

Hard to argue with the frustration here — SXTP has been a grinder, and the dilution scars are real. But the Jan 8 investor webinar was the first time in a while the story felt more structured than reactive. The Jan 20 1-for-4 reverse split is about survival (Nasdaq compliance), not value by itself. What actually matters is that B-FREE for chronic babesiosis is now enrolling at Mount Sinai, which shifts this from “hope and charts” to clinical execution. With ARAKODA already FDA-approved and a Type B FDA meeting expected in 2026, this finally has a path where data — not financing — decides the outcome. We’ve all seen SXTP spike and fade before; whether this version is different comes down to trial progress, not hype. Watching execution closely from here.

60 Degrees Pharmaceuticals (Nasdaq: SXTP) Investor Webinar - January 8, 2026



Weekly Chart
https://schrts.co/vDWEbPuw

absolute dissapointment, so what to do, buy more at these prices which i have done. Our time will come.

done some trading on SXTP to make a little here and there, but at this price I maintain a full position. I believe we'll get a really nice spike at the right time

Market is sleeping on this one

I have continued to trade SXTP, recently took some profits on the spike up. This is a great price to get in with what they have.

Then it $hit the bed, not looking good here.

Canine bump up $2.81

SXTP chart has potential no doubt about it

Should get a bump tomorrow and Thursday. Data will be released and if good, blue sky breakout.

I might have to nibble here looks good…

This is going to run starting Wednesday. Get ready for the data news release this week, then boom.

Runner Runner next week starting, showdown will start Wednesday.

SXTP................................................https://stockcharts.com/h-sc/ui?s=SXTP&p=W&b=5&g=0&id=p86431144783

SXTP under $2

SXTP, new 52 week low

SXTP: And they just DUMPED!! Dilution!!!

SXTP: NICE one for yah!! (As usual!! Yah got it 2-days ago, & scalped it today like a wild INDIAN at the Big Horn River!!)

Flipped out .85s at $1.30 

SXTP: What a NASTY affliction this is!!!

"Babesiosis is a tick-borne illness caused by Babesia parasites that develop and multiply in red blood cells." (Boy, I HATE when that happens!!!)

Sorry got in yesterday thought I alerted 

SXTP: iHub's "Glenn" just NEVER alerts anybody about anything in a RAPID manner!!

and why?

and why?

sxtp////////////////////////////////////////////......................a/h

SXTP .95 + 10% January 29th year if the snake Fidelity BlackRock Vanguard may want to pump there China holdings for the next 2 weeks 

SXTP......................https://stockcharts.com/h-sc/ui?s=SXTP&p=W&b=5&g=0&id=p86431144783

SXTP.............................................https://stockcharts.com/h-sc/ui?s=SXTP&p=W&b=5&g=0&id=p86431144783

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
11/14/2024 02:31:00 PM

sxtp..............................https://stockcharts.com/h-sc/ui?s=sxtp&p=W&b=5&g=0&id=p86431144783

SXTP......................................https://stockcharts.com/h-sc/ui?s=SXTP&p=W&b=5&g=0&id=p86431144783

Smells good 

SXTP..................................https://stockcharts.com/h-sc/ui?s=SXTP&p=W&b=5&g=0&id=p86431144783

Turnaround?!

SXTP new 52 week low

missed the bottom or a bottom at .91 cant believe how much this has fallen. Turns out my lifetime cost is actually higher than I thought even with some decent trading, so I am disappointed with this trade to date. Nonetheless I believe in what they are pursuing and expecting a rebound at any time where I will take profits probably above 1.45

currently I am trying to buy back shares I had sold at higher prices, down here if you sell at say 1.90 and buy back at 1.30, youre doing good due to the % difference and leverage at the lower prices. I feel like the current price, after all this stock has gone thru, including the dilution, is decent, but on any spikes to 2 bucks I would do some selling and continue doing so at higher prices. Sometimes you are stuck in some of these for a while, you dont control the timing, the market does, but if you are patient enough, and its a good company, you're spike should eventually come.

Looks like an offering is going to drop at a $1